Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

PMVPPMV Pharmaceuticals, Inc.

Nasdaq · CIK 0001699382
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts226

Identity from submissions API

NamePMV Pharmaceuticals, Inc.
CIK0001699382
TickersPMVP
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN463218129
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(609) 642-6670
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
400 ALEXANDER PARK DRIVE
SUITE 301
PRINCETON
NJ
08540
NJ
Mailing address
400 ALEXANDER PARK DRIVE
SUITE 301
PRINCETON
NJ
08540
NJ

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

394 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-20 8-K 8-K 8.01,9.01 0001193125-26-470247 001-39539 261579232 34 175696 1 1
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-014414 005-91714 261561111 34 18471
2026-11-10 10-Q 10-Q 0001193125-26-454471 001-39539 261538040 34 9635248 1 1
2026-11-10 8-K 8-K 2.02,9.01 0001193125-26-454467 001-39539 261538024 34 395467 1 1
2026-10-05 4 xslF345X06/form4-10052026_081058.xml 0002156044-26-000004 5570
2026-10-05 3 xslF345X06/form3-10052026_081055.xml 0002156044-26-000002 8187
2026-10-05 8-K 8-K 5.02,7.01,9.01 0001193125-26-413254 001-39539 261438926 34 161807 1 1
2026-09-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001699737-26-000021 005-91714 261382021 34 20440
2026-09-02 8-K 8-K 1.01,8.01,9.01 0001193125-26-378838 001-39539 261352112 34 870990 1 1
2026-09-02 424B5 424B5 0001193125-26-378780 333-283349 261352032 33 635498
2026-08-31 424B3 424B3 0001193125-26-377000 333-283349 261347424 33 55608
2026-08-31 424B5 424B5 0001193125-26-376860 333-283349 261346876 33 656877
2026-08-31 8-K 8-K 8.01,9.01 0001193125-26-376723 001-39539 261346455 34 161850 1 1
2026-08-14 10-Q 10-Q 0001193125-26-350448 001-39539 261276230 34 8177119 1 1
2026-08-14 8-K 8-K 2.02,9.01 0001193125-26-350445 001-39539 261276216 34 366049 1 1
2026-07-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-009110 005-91714 261212677 34 8661
2026-07-10 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-002568 005-91714 261167602 34 7103
2026-06-05 4 xslF345X06/form4-06052026_080643.xml 0001644348-26-000003 5571
2026-06-05 4 xslF345X06/form4-06052026_080603.xml 0001124164-26-000002 5599
2026-06-05 4 xslF345X06/form4-06052026_080616.xml 0001329959-26-000002 10010
2026-06-05 4 xslF345X06/form4-06052026_080614.xml 0001797209-26-000002 5591
2026-06-05 4 xslF345X06/form4-06052026_080642.xml 0001579824-26-000003 5593
2026-06-05 8-K 8-K 5.07 0001193125-26-258466 001-39539 261066915 34 145417 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001012975-26-000440 005-91714 26986934 34 16504
2026-05-12 10-Q 10-Q 0001193125-26-218227 001-39539 26965929 34 7348707 1 1
2026-05-12 8-K 8-K 2.02,9.01 0001193125-26-218225 001-39539 26965924 34 332252 1 1
2026-05-04 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-005496 005-91714 26937757 34 8671
2026-04-22 ARS ARS 0001140361-26-016040 001-39539 26881340 34 1813182
2026-04-22 DEFA14A DEFA14A 0001140361-26-016039 001-39539 26881333 34 3269571
2026-04-22 DEF 14A DEF 14A 0001140361-26-016038 001-39539 26881324 34 5383047 1 1
2026-03-09 4 xslF345X05/form4-03092026_080319.xml 0002006668-26-000002 6315
2026-03-09 4 xslF345X05/form4-03092026_080354.xml 0001613482-26-000002 5427
2026-03-09 4 xslF345X05/form4-03092026_080350.xml 0001825192-26-000002 5439
2026-03-09 4 xslF345X05/form4-03092026_080314.xml 0001341642-26-000002 5407
2026-03-06 S-8 S-8 0001193125-26-095224 333-294078 26728723 33 190268 1 1
2026-03-06 8-K 8-K 2.02,9.01 0001193125-26-095094 001-39539 26728540 34 326915 1 1
2026-03-06 10-K 10-K 0001193125-26-095014 001-39539 26728498 34 13142643 1 1
2026-03-04 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000947871-26-000231 005-91714 26723899 34 25125
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-26-001163 005-91714 26642472 34 6932
2026-02-09 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001373604-26-000014 005-91714 26610922 34 6482
2025-11-12 10-Q 10-Q 0001193125-25-276003 001-39539 251469049 34 8350957 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001193125-25-276000 001-39539 251469035 34 380997 1 1
2025-11-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-016264 005-91714 251469030 34 8648
2025-10-29 4 xslF345X05/form4-10292025_081048.xml 0001341642-25-000004 10206
2025-10-27 4 xslF345X05/ownership.xml 0000947871-25-000927 8064
2025-10-27 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000947871-25-000926 005-91714 251420613 34 24598
2025-10-23 144 xsl144X01/primary_doc.xml 0000947871-25-000922 001-39539 251413964 33 5524
2025-09-23 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-014073 005-91714 251335005 34 26261
2025-09-12 4 xslF345X05/ownership.xml 0000947871-25-000854 8059
2025-09-10 144 xsl144X01/primary_doc.xml 0000947871-25-000847 001-39539 251306873 33 4842
2025-09-10 8-K 8-K 7.01,8.01,9.01 0001193125-25-199857 001-39539 251305186 34 5546978 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-078560 005-91714 251218528 34 12887
2025-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-011954 005-91714 251210504 34 8572
2025-08-07 10-Q 10-Q 0000950170-25-104588 001-39539 251191700 34 8156328 1 1
2025-08-07 8-K 8-K 2.02,9.01 0000950170-25-104587 001-39539 251191698 34 326803 1 1
2025-07-03 4 xslF345X05/form4-07032025_110750.xml 0001415889-25-019386 5043
2025-07-03 4 xslF345X05/form4-07032025_110708.xml 0001415889-25-019384 4860
2025-07-03 4 xslF345X05/form4-07032025_110716.xml 0001415889-25-019382 4873
2025-07-03 4 xslF345X05/form4-07032025_110757.xml 0001415889-25-019380 7939
2025-06-09 4 xslF345X05/form4-06092025_080633.xml 0001415889-25-016276 5404
2025-06-09 4 xslF345X05/form4-06092025_080646.xml 0001415889-25-016269 5462
2025-06-09 4 xslF345X05/form4-06092025_080655.xml 0001415889-25-016266 5409
2025-06-09 4 xslF345X05/form4-06092025_080644.xml 0001415889-25-016262 9873
2025-06-09 4 xslF345X05/form4-06092025_080616.xml 0001415889-25-016259 5454
2025-06-09 4 xslF345X05/form4-06092025_080615.xml 0001415889-25-016254 5456
2025-06-09 8-K 8-K 5.07 0001193125-25-137497 001-39539 251032946 34 145431 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-049430 005-91714 25952925 34 13433
2025-05-09 10-Q 10-Q 0000950170-25-067513 001-39539 25928434 34 7744889 1 1
2025-05-09 8-K 8-K 2.02,9.01 0000950170-25-067511 001-39539 25928430 34 329147 1 1
2025-04-25 ARS ARS 0001140361-25-015613 001-39539 25870197 34 1804473
2025-04-25 DEFA14A DEFA14A 0001140361-25-015612 001-39539 25870191 34 819612
2025-04-25 DEF 14A DEF 14A 0001140361-25-015610 001-39539 25870182 34 5388996 1 1
2025-04-23 3 xslF345X02/form3-04232025_100400.xml 0001415889-25-011229 15021
2025-04-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-005584 005-91714 25821591 34 8461
2025-03-05 4 xslF345X05/form4-03052025_110309.xml 0001415889-25-007075 5440
2025-03-05 4 xslF345X05/form4-03052025_110323.xml 0001415889-25-007073 6445
2025-03-05 4 xslF345X05/form4-03052025_110346.xml 0001415889-25-007071 9359
2025-03-03 10-K 10-K 0000950170-25-030414 001-39539 25694122 34 14347350 1 1
2025-03-03 8-K 8-K 2.02,9.01 0000950170-25-030407 001-39539 25693821 34 374436 1 1
2025-02-21 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-016122 005-91714 25651605 34 20033
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001373604-25-000029 005-91714 25624419 34 6599
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001373604-25-000028 005-91714 25624334 34 6500
2025-02-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-002314 005-91714 25604796 34 8473
2025-01-28 S-8 S-8 0001193125-25-014448 333-284560 25565283 33 88080
2025-01-22 4 xslF345X05/form4-01222025_090129.xml 0001415889-25-001853 13403
2024-12-12 SC 13G pmvp13g.htm 0001373604-24-000110 005-91714 241543941 34 56216
2024-11-27 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-11-27 16:30:00 9999999995-24-003606 333-283349 241512993 33 1779
2024-11-27 424B3 424B3 0001193125-24-267229 333-283349 241511958 33 379120
2024-11-25 CORRESP filename1.htm 0001193125-24-265243 7645
2024-11-25 UPLOAD filename1.pdf 0000000000-24-013056 333-283349 40095
2024-11-20 S-3 S-3 0001193125-24-262148 333-283349 241478317 33 885874
2024-11-14 SC 13G/A arrowmark-pmvp093024a1.htm 0001172661-24-004898 005-91714 241459350 34 53978
2024-11-07 10-Q 10-Q 0000950170-24-122817 001-39539 241433267 34 7331079 1 1
2024-11-07 8-K 8-K 2.02,9.01 0000950170-24-122816 001-39539 241433262 34 365451 1 1
2024-10-03 4 xslF345X05/form4-10032024_081022.xml 0001415889-24-024627 15553
2024-10-03 4 xslF345X05/form4-10032024_081040.xml 0001415889-24-024624 15544
2024-10-03 4 xslF345X05/form4-10032024_081002.xml 0001415889-24-024622 15532
2024-09-12 4 xslF345X05/form4-09122024_100948.xml 0001415889-24-023313 4799
2024-09-12 4 xslF345X05/form4-09122024_090908.xml 0001415889-24-023309 4793
2024-08-14 SC TO-I/A SC TO-I/A 0001193125-24-200605 005-91714 241207342 34 18398
2024-08-08 10-Q 10-Q 0000950170-24-093343 001-39539 241186131 34 6872547 1 1
2024-08-08 8-K 8-K 1.02,2.02,9.01 0000950170-24-093345 001-39539 241186126 34 456949 1 1
2024-07-16 SC TO-I SC TO-I 0001193125-24-179366 005-91714 241118646 34 10864389
2024-07-08 SC 13G/A us69353y1038_070824.txt 0001086364-24-008191 005-91714 241105173 34 12764
2024-06-10 4 xslF345X05/form4-06102024_080637.xml 0001415889-24-016238 10250
2024-06-10 4 xslF345X05/form4-06102024_080620.xml 0001415889-24-016236 10185
2024-06-10 4 xslF345X05/form4-06102024_080647.xml 0001415889-24-016214 10277
2024-06-10 4 xslF345X05/form4-06102024_080606.xml 0001415889-24-016208 14786
2024-06-10 4 xslF345X05/form4-06102024_080652.xml 0001415889-24-016202 10304
2024-06-10 4 xslF345X05/form4-06102024_080633.xml 0001415889-24-016199 10349
2024-06-07 8-K 8-K 5.07 0001193125-24-156745 001-39539 241027470 34 150560 1 1
2024-05-09 10-Q 10-Q 0000950170-24-056295 001-39539 24928673 34 6362863 1 1
2024-05-09 8-K 8-K 2.02,9.01 0000950170-24-056294 001-39539 24928662 34 301722 1 1
2024-04-24 ARS ARS 0001140361-24-021598 001-39539 24866773 34 1803681
2024-04-24 DEFA14A DEFA14A 0001140361-24-021597 001-39539 24866767 34 1934310
2024-04-24 DEF 14A DEF 14A 0001140361-24-021596 001-39539 24866759 34 2833775
2024-04-09 SC 13G/A FILING PMV PHARMACEUTICALS, INC. 0000019617-24-000303 005-91714 34 89739
2024-02-29 10-K 10-K 0000950170-24-023062 001-39539 24703571 34 25571024 1 1
2024-02-29 8-K 8-K 2.02,9.01 0000950170-24-023058 001-39539 24703529 34 331169 1 1
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023955 005-91714 24640025 34 137699
2024-02-14 SC 13G/A ff3027171_13ga3-pmv.htm 0000895345-24-000060 005-91714 24637541 34 171192
2024-02-14 SC 13G arrowmark-pmvp123123.htm 0001172661-24-001360 005-91714 24636985 34 53957
2024-02-14 SC 13G/A PMV PHARMACEUTICALS, INC. 0000902664-24-001604 005-91714 24633016 34 57894
2024-02-14 SC 13G/A PMV PHARMACEUTICALS, INC. 0000902664-24-001575 005-91714 24632392 34 61794
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-021730 005-91714 24629297 34 12999
2024-01-29 SC 13G/A us69353y1038_012924.txt 0001086364-24-005056 005-91714 24573074 34 13327
2024-01-24 S-8 S-8 0001193125-24-013722 333-276667 24554452 33 82213
2024-01-23 SC 13G/A FILING PMV PHARMACEUTICALS, INC. 0000019617-24-000129 005-91714 34 89951
2024-01-23 SC 13G/A PMV_Pharma_Inc.txt 0000093751-24-000075 005-91714 24550593 34 8355
2024-01-22 4 FORM 4 SUBMISSION 0001209191-24-001999 9920
2024-01-22 4 FORM 4 SUBMISSION 0001209191-24-001995 7176
2024-01-22 4 FORM 4 SUBMISSION 0001209191-24-001993 12545
2024-01-18 8-K 8-K 2.05,7.01,9.01 0001193125-24-010177 001-39539 24541775 34 163862 1 1
2024-01-11 3 FORM 3 SUBMISSION 0001209191-24-001449 10792
2024-01-05 8-K 8-K 5.02,7.01,9.01 0001193125-24-003348 001-39539 24516171 34 174826 1 1
2023-11-24 4 xslF345X05/ownership.xml 0000947871-23-001104 11069
2023-11-22 144 xsl144X01/primary_doc.xml 0000947871-23-001098 001-39539 231433460 33 4662
2023-11-13 4 FORM 4 SUBMISSION 0001209191-23-054997 12238
2023-11-09 10-Q 10-Q 0000950170-23-061551 001-39539 231390140 34 7758467 1 1
2023-11-09 8-K 8-K 2.02,9.01 0000950170-23-061552 001-39539 231390136 34 426937 1 1
2023-10-12 8-K 8-K 8.01,9.01 0001193125-23-255083 001-39539 231323301 34 3102726 1 1
2023-10-11 8-K 8-K 7.01,9.01 0001193125-23-254135 001-39539 231320714 34 164009 1 1
2023-09-18 4 FORM 4 SUBMISSION 0001209191-23-049759 4765
2023-09-18 4 FORM 4 SUBMISSION 0001209191-23-049751 4759
2023-08-23 SC 13D/A AMENDMENT NO. 2 0000947871-23-000902 005-91714 231198176 34 110742
2023-08-09 10-Q 10-Q 0000950170-23-040153 001-39539 231153433 34 8393515 1 1
2023-08-09 8-K 8-K 2.02,9.01 0000950170-23-040151 001-39539 231153423 34 473996 1 1
2023-08-08 4 FORM 4 SUBMISSION 0001209191-23-045010 9753
2023-07-07 SC 13G/A us69353y1038_070723.txt 0001306550-23-009586 005-91714 231077295 34 13377
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036456 5269
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036449 5327
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036427 5282
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036383 10010
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036373 5319
2023-06-12 4 FORM 4 SUBMISSION 0001209191-23-036368 5321
2023-06-09 8-K 8-K 5.07 0001193125-23-164011 001-39539 231003903 34 149838 1 1
2023-05-19 SC 13G SC 13G 0001104659-23-062680 005-91714 23940008 34 131537
2023-05-15 4 FORM 4 SUBMISSION 0001209191-23-029612 5331
2023-05-15 4 FORM 4 SUBMISSION 0001209191-23-029609 5323
2023-05-15 4 FORM 4 SUBMISSION 0001209191-23-029594 5288
2023-05-15 4 FORM 4 SUBMISSION 0001209191-23-029586 5279
2023-05-10 SC 13G/A PMV_PHARMACEUTICALS_INC.txt 0000093751-23-000561 005-91714 23904601 34 8291
2023-05-10 10-Q 10-Q 0000950170-23-020100 001-39539 23904410 34 7838162 1 1
2023-05-10 8-K 8-K 2.02,9.01 0000950170-23-020097 001-39539 23904402 34 391843 1 1
2023-04-28 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-23-056275,2023-04-28 9999999995-23-001090 333-260012 23869665 33 1680
2023-04-28 ARS ARS 0001140361-23-021225 001-39539 23860293 34 1937941
2023-04-28 DEFA14A DEFA14A 0001140361-23-021223 001-39539 23860282 34 2574606
2023-04-28 8-K 8-K 5.03,9.01 0001193125-23-124381 001-39539 23860271 34 360673 1 1
2023-04-28 DEF 14A DEF14A 0001140361-23-021220 001-39539 23860268 34 2754088
2023-03-01 POS AM POS AM 0001193125-23-056275 333-260012 23693327 33 1271892
2023-03-01 10-K 10-K 0000950170-23-005345 001-39539 23689852 34 14383149 1 1
2023-03-01 8-K 8-K 2.02,9.01 0000950170-23-005343 001-39539 23689843 34 393622 1 1
2023-03-01 POSASR POSASR 0001193125-23-055105 333-260012 23689666 33 1329499
2023-02-14 SC 13G/A ff0001742120_13ga-pmv.htm 0000895345-23-000138 005-91714 23626170 34 166268
2023-02-14 SC 13G/A PMV PHARMACEUTICALS, INC. 0000902664-23-001721 005-91714 23623851 34 64066
2023-02-14 SC 13G/A PMV PHARMACEUTICALS, INC. 0000902664-23-001676 005-91714 23623488 34 58687
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-020811 005-91714 23622833 34 137772
2023-02-10 SC 13G/A SC 13G/A 0001193125-23-032082 005-91714 23610050 34 107496
2023-02-10 SC 13G/A PMV_Pharmaceuticals_Inc.txt 0000093751-23-000444 005-91714 23609499 34 10252
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-016743 005-91714 23604026 34 12920
2023-01-31 SC 13G/A us69353y1038_013123.txt 0001306550-23-005159 005-91714 23571819 34 13249
2023-01-30 4 FORM 4 SUBMISSION 0001209191-23-005476 4638
2023-01-25 SC 13G/A FILING PMV PHARMACEUTICALS, INC. 0000019617-23-000152 005-91714 34 89736
2023-01-25 S-8 S-8 0001193125-23-014435 333-269394 23549438 33 102123
2023-01-24 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-23-000338 005-91714 23547800 34 27166
2022-11-08 4 FORM 4 SUBMISSION 0001209191-22-056102 9933
2022-11-08 3 FORM 3 SUBMISSION 0001209191-22-056097 5090
2022-11-08 10-Q 10-Q 0000950170-22-022920 001-39539 221367321 34 8615086 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-022919 001-39539 221367313 34 487178 1 1
2022-11-04 8-K 8-K 5.02,7.01,9.01 0001193125-22-277423 001-39539 221360220 34 162113 1 1
2022-09-13 4 FORM 4 SUBMISSION 0001209191-22-049694 4771
2022-09-13 4 FORM 4 SUBMISSION 0001209191-22-049692 4758
2022-08-09 10-Q 10-Q 0000950170-22-015767 001-39539 221146474 34 7563832 1 1
2022-08-09 8-K 8-K 2.02,9.01 0000950170-22-015768 001-39539 221146469 34 485731 1 1
2022-07-11 SC 13G PMV_PHARMACEUTICALS_INC.txt 0000093751-22-000570 005-91714 221076519 34 10202
2022-07-07 SC 13G/A FILING PMV PHARMACEUTICALS, INC. 0000019617-22-000407 005-91714 34 89788
2022-06-17 SC 13G PMV PHARMACEUTICALS, INC. 0001104659-22-072372 005-91714 221023690 34 133739
2022-06-08 8-K 8-K 7.01,9.01 0001193125-22-169686 001-39539 221002524 34 10763552 1 1
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034634 5224
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034622 5297
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034620 5252
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034618 5289
2022-06-06 4 FORM 4 SUBMISSION 0001209191-22-034607 5289
2022-06-06 8-K 8-K 5.07 0001193125-22-168285 001-39539 22997964 34 161195 1 1
2022-05-31 4 xslF345X03/ownership.xml 0000947871-22-000675 11722
2022-05-26 8-K 8-K 7.01,9.01 0001564590-22-021434 001-39539 22971081 34 202495 1 1
2022-05-10 10-Q 10-Q 0001564590-22-019071 001-39539 22907348 34 6236542 1 1
2022-05-10 8-K 8-K 2.02,9.01 0001564590-22-019070 001-39539 22907339 34 372882 1 1
2022-04-29 4 FORM 4 SUBMISSION 0001209191-22-026341 10038
2022-04-22 DEFA14A DEFA14A 0001140361-22-015509 001-39539 22843422 34 3963869
2022-04-22 DEF 14A DEF 14A 0001140361-22-015508 001-39539 22843418 34 2635475
2022-04-21 4 FORM 4 SUBMISSION 0001209191-22-025171 8579
2022-04-01 SC 13D/A AMENDMENT NO. 1 0000947871-22-000432 005-91714 22799290 34 140870
2022-03-31 4 xslF345X03/ownership.xml 0000947871-22-000429 17469
2022-03-09 4 FORM 4 SUBMISSION 0001209191-22-017591 11624
2022-03-01 10-K 10-K 0001564590-22-007860 001-39539 22693934 34 15496548 1 1
2022-03-01 8-K 8-K 2.02,9.01 0001564590-22-007858 001-39539 22693927 34 398531 1 1
2022-02-28 4 FORM 4 SUBMISSION 0001209191-22-013576 5303
2022-02-28 4 FORM 4 SUBMISSION 0001209191-22-013569 5293
2022-02-28 4 FORM 4 SUBMISSION 0001209191-22-013557 5258
2022-02-28 4 FORM 4 SUBMISSION 0001209191-22-013544 5249
2022-02-14 SC 13G/A SC 13G/A 0001140361-22-005366 005-91714 22634250 34 251228
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-041754 005-91714 22632202 34 85821
2022-02-14 SC 13G/A SC 13G/A 0001104659-22-022624 005-91714 22631031 34 123781
2022-02-14 SC 13G PMV PHARMACEUTICALS, INC. 0000902664-22-001593 005-91714 22625679 34 69523
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-039392 005-91714 22625163 34 163708
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-039277 005-91714 22625014 34 105447
2022-02-11 SC 13G/A PMV PHARMACEUTICALS, INC. 0000902664-22-001525 005-91714 22617356 34 59175
2022-02-10 SC 13G SCHEDULE 13G 0001104659-22-018348 005-91714 22610617 34 12886
2022-02-08 4 FORM 4 SUBMISSION 0001209191-22-007754 4623
2022-02-04 SC 13G us69353y1038_020422.txt 0000834237-22-007153 005-91714 22593443 34 13303
2022-01-26 SC 13G FILING PMV PHARMACEUTICALS, INC. 0000019617-22-000187 005-91714 34 89742
2022-01-24 S-8 S-8 0001193125-22-016010 333-262308 22549316 33 68961
2022-01-19 SC 13G COWEN FINANCIAL PRODUCTS LLC 0001085146-22-000226 005-91714 22538552 34 27128
2022-01-10 4 FORM 4 SUBMISSION 0001209191-22-002722 5231
2022-01-10 3 FORM 3 SUBMISSION 0001209191-22-002718 5045
2022-01-06 8-K FORM 8-K 5.02,7.01,9.01 0001193125-22-003158 001-39539 22513660 34 166314 1 1
2021-12-16 4 FORM 4 SUBMISSION 0001209191-21-070116 11622
2021-11-12 10-Q 10-Q 0001564590-21-056458 001-39539 211399556 34 7250984 1 1
2021-11-12 8-K 8-K 2.02,9.01 0001564590-21-056451 001-39539 211399529 34 440142 1 1
2021-10-18 SC 13G/A SC 13G/A 0001193125-21-300999 005-91714 211328281 34 165724
2021-10-08 4 FORM 4 SUBMISSION 0001209191-21-060100 5864
2021-10-05 8-K FORM 8-K 1.01,9.01 0001193125-21-292044 001-39539 211306668 34 411556 1 1
2021-10-04 4 FORM 4 SUBMISSION 0001209191-21-059163 9841
2021-10-04 S-3ASR S-3ASR 0001193125-21-290972 333-260012 211302959 33 971777
2021-09-29 4 FORM 4 SUBMISSION 0001209191-21-058091 8114
2021-09-24 4 FORM 4 SUBMISSION 0001209191-21-057711 5342
2021-09-23 4 FORM 4 SUBMISSION 0001209191-21-057515 4674
2021-09-21 4 FORM 4 SUBMISSION 0001209191-21-057099 5864
2021-09-13 4 FORM 4 SUBMISSION 0001209191-21-055782 12614
2021-09-10 4 FORM 4 SUBMISSION 0001209191-21-055438 8662
2021-09-08 4 FORM 4 SUBMISSION 0001209191-21-055140 8667
2021-09-02 4 FORM 4 SUBMISSION 0001209191-21-054604 10364
2021-08-30 4 FORM 4 SUBMISSION 0001209191-21-053964 14863
2021-08-25 4 FORM 4 SUBMISSION 0001209191-21-053389 12613
2021-08-24 4 FORM 4 SUBMISSION 0001209191-21-053179 4674
2021-08-20 4 FORM 4 SUBMISSION 0001209191-21-052822 12613
2021-08-20 4 FORM 4 SUBMISSION 0001209191-21-052787 8593
2021-08-20 4 FORM 4 SUBMISSION 0001209191-21-052784 8564
2021-08-18 4 FORM 4 SUBMISSION 0001209191-21-052248 9148
2021-08-17 4 FORM 4 SUBMISSION 0001209191-21-051994 17113
2021-08-13 10-Q 10-Q 0001564590-21-044131 001-39539 211169595 34 6821025 1 1
2021-08-13 8-K 8-K 2.02,9.01 0001564590-21-044128 001-39539 211169578 34 293634
2021-08-12 4 FORM 4 SUBMISSION 0001209191-21-051285 14863
2021-08-10 4 FORM 4 SUBMISSION 0001209191-21-050670 12663
2021-08-09 4 FORM 4 SUBMISSION 0001209191-21-050501 19359
2021-08-04 4 FORM 4 SUBMISSION 0001209191-21-049728 18839
2021-08-04 4 FORM 4 SUBMISSION 0001209191-21-049724 10782
2021-07-30 4 FORM 4 SUBMISSION 0001209191-21-048965 8113
2021-07-27 4 FORM 4 SUBMISSION 0001209191-21-048335 10362
2021-07-23 4 FORM 4 SUBMISSION 0001209191-21-047988 7591
2021-07-23 4 FORM 4 SUBMISSION 0001209191-21-047970 5189
2021-07-22 4 FORM 4 SUBMISSION 0001209191-21-047747 7503
2021-07-22 4 FORM 4 SUBMISSION 0001209191-21-047745 16072
2021-07-14 4 FORM 4 SUBMISSION 0000899243-21-028387 20508
2021-07-08 4 FORM 4 SUBMISSION 0001209191-21-046054 10301
2021-07-08 4 FORM 4 SUBMISSION 0001209191-21-045989 11021
2021-06-29 4 FORM 4 SUBMISSION 0001209191-21-043738 10327
2021-06-22 4 FORM 4 SUBMISSION 0001209191-21-042460 7027
2021-06-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-005709 32422
2021-06-11 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-005572 32368
2021-06-09 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-005496 45772
2021-06-09 4 FORM 4 SUBMISSION 0001209191-21-039245 5875
2021-06-09 4 FORM 4 SUBMISSION 0001209191-21-039241 5226
2021-06-09 4 FORM 4 SUBMISSION 0001209191-21-039239 5298
2021-06-09 4 FORM 4 SUBMISSION 0001209191-21-039237 5253
2021-06-09 4 FORM 4 SUBMISSION 0001209191-21-039235 5291
2021-06-08 4 FORM 4 SUBMISSION 0001209191-21-039038 5303
2021-06-08 4 FORM 4 SUBMISSION 0001209191-21-039035 13335
2021-06-08 4 FORM 4 SUBMISSION 0001209191-21-039032 5264
2021-06-08 4 FORM 4 SUBMISSION 0001209191-21-039028 5246
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038798 10301
2021-06-07 8-K 8-K 5.07 0001193125-21-184010 001-39539 21998791 34 25153
2021-06-04 4 FORM 4 SUBMISSION 0001209191-21-038419 8595
2021-06-02 4 FORM 4 SUBMISSION 0001209191-21-037377 5863
2021-06-02 4 FORM 4 SUBMISSION 0001209191-21-037144 34825
2021-05-27 4 FORM 4 SUBMISSION 0001209191-21-036352 8112
2021-05-24 4 FORM 4 SUBMISSION 0001209191-21-035544 10363
2021-05-24 4 FORM 4 SUBMISSION 0001209191-21-035364 16373
2021-05-21 4 FORM 4 SUBMISSION 0001209191-21-035034 7026
2021-05-21 S-8 FORM S-8 0001193125-21-168601 333-256346 21946624 33 79451
2021-05-14 10-Q 10-Q 0001564590-21-027813 001-39539 21921993 34 5115815 1
2021-05-14 8-K 8-K 2.02,9.01 0001564590-21-027811 001-39539 21921981 34 264688
2021-05-12 4 FORM 4 SUBMISSION 0001209191-21-032222 5863
2021-05-12 4 FORM 4 SUBMISSION 0000899243-21-019183 20458
2021-05-10 4 FORM 4 SUBMISSION 0001209191-21-031300 11013
2021-05-07 4 FORM 4 SUBMISSION 0001209191-21-031052 5862
2021-05-07 SC 13G/A SC 13G/A 0001193125-21-155060 005-91714 21903744 34 152578
2021-05-07 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-004263 20664
2021-05-04 4 FORM 4 SUBMISSION 0001209191-21-030096 12336
2021-04-23 DEFA14A DEFA14A 0001140361-21-014038 001-39539 21846785 34 270918
2021-04-23 DEF 14A DEF 14A 0001140361-21-014036 001-39539 21846779 34 1872017
2021-04-13 4 FORM 4 SUBMISSION 0001209191-21-026547 14336
2021-04-08 4 FORM 4 SUBMISSION 0001209191-21-026157 16590
2021-04-08 4 FORM 4 SUBMISSION 0001209191-21-026064 11013
2021-04-07 4 FORM 4 SUBMISSION 0001209191-21-025880 5227
2021-04-07 3 FORM 3 SUBMISSION 0001209191-21-025874 5836
2021-04-06 8-K 8-K 5.02,7.01,9.01 0001193125-21-107069 001-39539 21808210 34 32911
2021-04-05 4 FORM 4 SUBMISSION 0001209191-21-025463 10365
2021-03-31 4 FORM 4 SUBMISSION 0001209191-21-023909 22872
2021-03-26 4 FORM 4 SUBMISSION 0001209191-21-023299 21593
2021-03-25 4 FORM 4 SUBMISSION 0000899243-21-013532 20463
2021-03-03 10-K 10-K 0001564590-21-010578 001-39539 21709153 34 11440435 1
2021-03-03 8-K 8-K 2.02,9.01 0001564590-21-010576 001-39539 21709123 34 214960
2021-02-16 SC 13G SC 13G 0001104659-21-023842 005-91714 21637714 34 97732
2021-02-16 SC 13G/A AMENDMENT NO. 1 0001387131-21-002334 005-91714 21631248 34 206383
2021-02-12 SC 13G SC 13G 0001193125-21-041409 005-91714 21626985 34 142610
2021-02-12 SC 13G PMV PHARMACEUTICALS, INC. 0000902664-21-001243 005-91714 21622926 34 61870
2021-02-12 SC 13G SC 13G 0001193125-21-039677 005-91714 21622525 34 113990
2020-12-31 4 FORM 4 SUBMISSION 0001209191-20-065683 9134
2020-11-20 4 FORM 4 SUBMISSION 0001209191-20-059634 8922
2020-11-13 10-Q 10-Q 0001564590-20-053908 001-39539 201312356 34 6423378 1
2020-11-13 8-K 8-K 2.02,9.01 0001564590-20-053736 001-39539 201309252 34 290517
2020-11-12 4 FORM 4 SUBMISSION 0001209191-20-057925 5985
2020-10-05 SC 13D SCHEDULE 13D 0000947871-20-000773 005-91714 201224547 34 144446
2020-10-05 SC 13G ACQUISITION OF BENEFICIAL OWNERSHIP 0001387131-20-008767 005-91714 201224345 34 161244
2020-10-02 4/A FORM 4/A SUBMISSION 0001209191-20-053346 21879
2020-10-02 4/A FORM 4/A SUBMISSION 0001209191-20-053342 26960
2020-09-30 SC 13G SC 13G 0001193125-20-259677 005-91714 201212601 34 102329
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052353 18021
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052351 7462
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052350 31828
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052349 3224
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052347 2996
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052346 3000
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052341 27699
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052339 35318
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052337 30373
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052336 11865
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052335 26754
2020-09-29 4 FORM 4 SUBMISSION 0001209191-20-052334 21674
2020-09-29 3/A FORM 3/A SUBMISSION 0001209191-20-052333 12580
2020-09-29 4 OWNERSHIP DOCUMENT 0001104659-20-109853 14176
2020-09-29 8-K 8-K 5.03,7.01,9.01 0001193125-20-257820 001-39539 201209015 34 212968
2020-09-28 S-8 S-8 0001193125-20-256300 333-249094 201204378 33 92467
2020-09-25 424B4 424B4 0001193125-20-254551 333-248627 201200144 33 3703260
2020-09-24 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-09-24 16:00:00 9999999995-20-002572 333-248627 201196713 33 1662
2020-09-24 3 OWNERSHIP DOCUMENT 0001104659-20-108403 9084
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052031 4706
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052030 6604
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052029 14152
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052026 19741
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052022 6200
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052015 5938
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052011 5946
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052007 14362
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052005 14958
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052003 6547
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-052001 8590
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051999 14311
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051998 9727
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051997 5961
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051996 18574
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051995 7856
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051994 6640
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051993 10029
2020-09-24 3 FORM 3 SUBMISSION 0001209191-20-051991 12025
2020-09-24 CERT 8A_Cert_PMVP.pdf 0001354457-20-000522 001-39539 201193877 34 140356
2020-09-24 S-1/A S-1/A 0001193125-20-252783 333-248627 201193483 33 3806936
2020-09-22 CORRESP filename1.htm 0001193125-20-251102 9949
2020-09-22 CORRESP filename1.htm 0001193125-20-251101 10782
2020-09-21 8-A12B 8-A12B 0001193125-20-250157 001-39539 201186382 34 14012
2020-09-21 CORRESP filename1.htm 0001193125-20-249576 20453
2020-09-21 S-1/A S-1/A 0001193125-20-249570 333-248627 201185145 33 4992826
2020-09-17 UPLOAD filename1.pdf 0000000000-20-008764 44376
2020-09-11 CORRESP filename1.htm 0001193125-20-243785 134965
2020-09-04 CORRESP filename1.htm 0001193125-20-240145 25056
2020-09-04 S-1 S-1 0001193125-20-240132 333-248627 201162228 33 5764670
2020-08-18 UPLOAD filename1.pdf 0000000000-20-007585 45918
2020-08-03 DRS/A filename1.htm 0000950123-20-007493 377-03247 201067321 33 3786081
2020-07-31 DRSLTR filename1.htm 0000950123-20-007494 59338
2020-07-23 UPLOAD filename1.pdf 0000000000-20-006725 67032
2020-06-26 DRS filename1.htm 0000950123-20-006405 377-03247 20993917 33 3398053
2017-03-02 D xslFormDX01/primary_doc.xml 06b 0001699382-17-000001 021-281658 17658233 33 8769

Latest XBRL company facts

One latest value per concept from companyfacts (226 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 75.53M 2026-11-10 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
dei EntityPublicFloat Entity Public Float USD 53.44M 2025-06-30 2025 FY 10-K 2026-03-06 0001193125-26-095014
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 662,535 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001140361-26-016038
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 898,197 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001140361-26-016038
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 958,175 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001140361-26-016038
ecd PeoTotalCompAmt PeoTotalCompAmt USD 1.67M 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001140361-26-016038
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 14.37 2025-01-01 2025-12-31 DEF 14A 2026-04-22 0001140361-26-016038
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.64M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 8.91M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 910,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 1.35M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -156,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 574.21M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 1.60M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 20,359 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 4.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 58.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap Assets Assets USD 111.40M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AssetsCurrent Assets, Current USD 104.89M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 168,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 108.64M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 108.48M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 28.21M 2019-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap Cash Cash USD 254,000 2023-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-061551
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 19.99M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 108.52M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 19.99M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -17.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 19.99M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 1.21 2026-09-02 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 41.95M 2026-09-02 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 17.49M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 1.00B 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 75.53M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 75.53M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -70.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 22.87M 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD -2.17M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 22,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD -2.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap DebtSecuritiesAvailableForSaleUnrealizedGainLoss Debt Securities, Available-for-sale, Unrealized Gain (Loss) USD 1.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap DeferredRentCredit Deferred Rent Credit USD 88,000 2021-03-31 2021 Q1 10-Q 2021-05-14 0001564590-21-027813
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 117.81M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 265,000 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 68.59M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 11.79M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 3.68M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 1.21M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 117.54M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 265,000 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 27,000 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap Depreciation Depreciation USD 81,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap DividendsCommonStock Dividends, Common Stock USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap DividendsPreferredStock Dividends, Preferred Stock USD 0 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.22 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.79 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-015767
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.22 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.03 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.22 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.03 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023062
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.02 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.03 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount USD 305,000 2018-12-31 2020 Q3 10-Q 2020-11-13 0001564590-20-053908
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 11.27M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 12.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings USD 143,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 51,000 2019-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -24,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD 24,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 11.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -79.94M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -70.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 23,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 23,000 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-29 0000950170-24-023062
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 17.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 6,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -16.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -1.84M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 745,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 2.54M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -1.52M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 1.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD 241,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030414
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 24,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD 2.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap LeaseCost Lease, Cost USD 387,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 1.01M 2021-03-31 2021 Q1 10-Q 2021-05-14 0001564590-21-027813
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 413,000 2021-03-31 2021 Q1 10-Q 2021-05-14 0001564590-21-027813
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 71,000 2021-03-31 2021 Q1 10-Q 2021-05-14 0001564590-21-027813
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 525,000 2021-03-31 2021 Q1 10-Q 2021-05-14 0001564590-21-027813
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap Liabilities Liabilities USD 54.30M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 111.40M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap LiabilitiesCurrent Liabilities, Current USD 10.69M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 43.61M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap MarketableSecurities Marketable Securities USD 88.52M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 82.57M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 5.96M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 47.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -12.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -52.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -70.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingExpenses Operating Expenses USD 57.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -57.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeaseCost Operating Lease, Cost USD 269,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 269,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 138,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 138,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeasePayments Operating Lease, Payments USD 717,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 133,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 735,000 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 479,000 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 4,000 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 252,000 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 120,000 2020-09-30 2020 Q3 10-Q 2020-11-13 0001564590-20-053908
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 1.18M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001564590-21-056458
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.137 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 97.67M 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 152,000 2022-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 291,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -244,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD 4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -240,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -76,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 51,000 2019-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -12.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 3.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 78.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PaymentsToAcquireProductiveAssets Payments to Acquire Productive Assets USD 6,000 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 2.33M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 35.12M 2023-01-01 2023-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 69.79M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 143,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 65.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ProceedsFromSaleOfMachineryAndEquipment Proceeds from Sale of Machinery and Equipment USD 29,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-122817
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 1,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-12 0001193125-26-218227
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -70.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 1.48M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 131,000 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap PurchaseCommitmentRemainingMinimumAmountCommitted Purchase Commitment, Remaining Minimum Amount Committed USD 0 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap ReclassificationsOfTemporaryToPermanentEquity Reclassifications of Temporary to Permanent Equity USD -238.72M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 46.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap RestrictedCash Restricted Cash USD 0 2025-06-30 2025 Q2 10-Q 2025-08-07 0000950170-25-104588
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 177.46M 2021-09-30 2021 Q3 10-Q 2021-11-12 0001564590-21-056458
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 822,000 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030414
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -516.95M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-276003
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 4.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value USD/shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 0 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 0 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period shares 907,665 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value USD/shares 1.8 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.773 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-12 0001193125-26-218227
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.778 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.769 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.038 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-12 0001193125-26-218227
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.051 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 4.34M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 1.04M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 7.99M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 2.9 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 117,680 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 4.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 2.58 2018-01-01 2018-12-31 2020 Q3 10-Q 2020-11-13 0001564590-20-053908
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 2.85M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 16.38M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 2.17 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 2.85M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 16.38M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 2.17 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 154.07M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 2.59M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-03 0001564590-21-010578
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.37 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 1.98 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.48 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 57.11M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 5.265 2020-09-24 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 19,310 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 238.72M 2020-01-01 2020-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 18.42M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 10,000 2025-01-01 2025-03-31 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 168.93M 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 169.38M 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 22.88M 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 22.87M 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 22.87M 2019-12-31 2021 FY 10-K 2022-03-01 0001564590-22-007860
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 4.03M 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 773,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-06 0001193125-26-095014
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 43,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-01 0000950170-23-005345
us-gaap VariableLeaseCost Variable Lease, Cost USD 18,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 43.61M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 57.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 45.52M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-09 0000950170-22-015767
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 57.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471
us-gaap WorkersCompensationLiabilityCurrent Workers' Compensation Liability, Current USD 4.13M 2026-09-30 2026 Q3 10-Q 2026-11-10 0001193125-26-454471

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →